Big Pharms better start to buy some MNKD stocks now while it's still cheap to hedge their potential loss on RAA revenue.
Could be due to summer vacation time for doctors. Lots of doctors take one or two weeks vacation during this time frame.
during the first 6 months, the monthly growth rate is about 45%. If the trend continues, this week's script count should be about 434 * 1.45 = 613 (434 is week 20's script count). So your prediction should be reasonable.
For RAA like Humalog, the dosing is actually kept low to avoid hypo due to the long tail. For afrezza, there is no such worry, so you can take more dose to prevent the post-meal spike. So it's not really a disadvantage that you have to take more afrezza than humalog, but really a benefit that allows you to take more afrezza insulin to give better glucose level control, and hence, the A1C drop.
I guess SINA will announce soon. Otherwise, it won't be able to buyout cheap as the stock price keeps rising.
When a brokerage have to close a margin requirement, it will buy with market price. If there is no enough shares to buy at BO price (imagine naked short), then the price will go beyond BO price.
Theoretically, it can even go beyond 100% of float. Shorted shares are bought by longs which can be lent out again for short. However, at certain point, brokerage will put up a brake as the risk is too high (remember the VW short squeeze?)
SINA can easily fetch a 2X market cap if relisting in Chinese stock exchange, can't see any reason why not following the trend.
This is non-sense. SINA SP has stayed in 30s for very long time. Any shareholders can buy from the market before the CEO purchase.
The doctor could be misleading the journalist? Did he ever tell his patients aabout afrezza and how afrezza works? If he didn't, how could he conclude that his patients don't want to switch?
The reason HALO wants to use PFS as primary P3 endpoint is to shorten the trial time. If HALO did not expect much longer OS time than PFS time, then there is no point to take the risk of using PFS as primary endpoint.
PEGPH20 is needed for any future pancreatic cancer drug in high HA patients, as any drug needs to reach the tumor cell for it to work well. That's the beauty of PEGPH20, it's less likely to be replaced by future drugs coming to the market.
That's true. I had a comment on OMED board that they need to combine their pancreatic cancer drug in clinical trial with PEGPH20, otherwise, their number will not be able to math HALO's, even though the two drugs are not really competing with each other.
Will Intel take the risk to miss the boat again?